Citation Impact
Citing Papers
Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World
2006 Standout
Circulating microRNAs as stable blood-based markers for cancer detection
2008 Standout
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
A graphene oxide-peptide fluorescence sensor for proteolytically active prostate-specific antigen
2012
The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials
2001 Standout
Lateral flow (immuno)assay: its strengths, weaknesses, opportunities and threats. A literature survey
2008 Standout
Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline
2010 Standout
Prostate cancer prevention
2007
Update on screening for prostate cancer with prostate-specific antigen
2004
Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism
2006
Defining the biologic role of genes that regulate prostate cancer metastasis
2000
The Risk–Benefit Profile of Commonly Used Herbal Therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava
2002 Standout
Dissemination and growth of cancer cells in metastatic sites
2002 Standout
Nomograms in oncology: more than meets the eye
2015 Standout
Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis
2010 Standout
Multiplexed electrical detection of cancer markers with nanowire sensor arrays
2005 Standout
Long Noncoding RNAs in Cancer Pathways
2016 Standout
Epidemiology of Prostate Cancer
2019 Standout
Oligosaccharide Profiles of the Prostate Specific Antigen in Free and Complexed Forms from the Prostate Cancer Patient Serum and in Seminal Plasma: a Glycopeptide Approach
2007
Carotenoids and human health
2007 Standout
Serum and Tissue Lycopene and Biomarkers of Oxidation in Prostate Cancer Patients: A Case-Control Study
1999
Prostate specific antigen: biology, biochemistry and available commercial assays
2001
High-throughput analysis of N-glycans using AutoTip via glycoprotein immobilization
2017
Optimization of phenolics and dietary fibre extraction from date seeds
2008 Standout
The case for early detection
2003 Nobel
Increased telomerase activity and comprehensive lifestyle changes: a pilot study
2008 StandoutNobel
EAU Guidelines on Prostate Cancer
2007 Standout
Comparative Population Genomics of the Ejaculate in Humans and the Great Apes
2013 StandoutNobel
The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free‐to‐total prostate‐specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?
2010
EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction
2013 Standout
One-step immunostrip test for the simultaneous detection of free and total prostate specific antigen in serum
2005
Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?
2009
Free-to-total prostate-specific antigen (PSA) ratio contributes to an increased rate of prostate cancer detection in a Japanese population screened using a PSA level of 2.1–10.0 ng/ml as a criterion
2008
A Pragmatic Guide to Enrichment Strategies for Mass Spectrometry–Based Glycoproteomics
2020 StandoutNobel
PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2
2015 Standout
Large-scale and high-confidence proteomic analysis of human seminal plasma
2006
The Human Plasma Proteome
2002 Standout
Cell surface glycoproteomic analysis of prostate cancer-derived PC-3 cells
2011 StandoutNobel
Cumulative Prostate Cancer Risk Assessment with the Aid of the Free-to-Total Prostate Specific Antigen Ratio
2003
Cancer as an evolutionary and ecological process
2006 Standout
Associations of lower urinary tract symptoms with prostate‐specific antigen levels, and screen‐detected localized and advanced prostate cancer: a case‐control study nested within the UK population‐based ProtecT (Prostate testing for cancer and Treatment) study
2008
Gold nanoparticles in biomedical applications: recent advances and perspectives
2011 Standout
Prostate-specific antigen
2000
Aberrant PSA glycosylation—a sweet predictor of prostate cancer
2013
Glycosylation in cancer: mechanisms and clinical implications
2015 Standout
Analytical performance of the Roche total and free PSA assays on the Elecsys 2010 immunoanalyzer
2002
Enhancement of sensitivity using hybrid stimulus for the diagnosis of prostate cancer based on polydiacetylene (PDA) supramolecules
2010
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
2013 Standout
Glycoproteomics
2022 StandoutNobel
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
2012 Standout
Serpin Structure, Mechanism, and Function
2002 Standout
Between-Method Differences in Prostate-Specific Antigen Assays Affect Prostate Cancer Risk Prediction by Nomograms
2011
SERUM PROTEOMIC PROFILING CAN DISCRIMINATE PROSTATE CANCER FROM BENIGN PROSTATES IN MEN WITH TOTAL PROSTATE SPECIFIC ANTIGEN LEVELS BETWEEN 2.5 AND 15.0 NG/ML
2004
EFFECT OF SOLUBLE AND INSOLUBLE FIBER DIETS ON SERUM PROSTATE SPECIFIC ANTIGEN IN MEN
2000
Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force
2008
Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?
2014
The Combination of Human Glandular Kallikrein and Free Prostate-specific Antigen (PSA) Enhances Discrimination Between Prostate Cancer and Benign Prostatic Hyperplasia in Patients with Moderately Increased Total PSA
1999
An anatomization on breast cancer detection and diagnosis employing multi-layer perceptron neural network (MLP) and Convolutional neural network (CNN)
2020 Standout
Prostate Specific Antigen Best Practice Statement: 2009 Update
2009
Electrochemiluminescence (ECL)
2004 Standout
PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome
2008
EFFECTS OF A SAW PALMETTO HERBAL BLEND IN MEN WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
2000
Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force
2002
Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention
2008
Heritability of Prostate-Specific Antigen and Relationship with Zonal Prostate Volumes in Aging Twins*
2000
Glyco-Analytical Multispecific Proteolysis (Glyco-AMP): A Simple Method for Detailed and Quantitative Glycoproteomic Characterization
2013
Inhibition of Prostate-Specific Antigen (PSA) by α1-Antichymotrypsin: Salt-Dependent Activation Mediated by a Conformational Change
2002
Water-Soluble Conjugated Polymers for Imaging, Diagnosis, and Therapy
2012 Standout
Prostate Cancer Detection in Patients With Total Serum Prostate-Specific Antigen Levels of 4–10 ng/mL: Diagnostic Efficacy of Diffusion-Weighted Imaging, Dynamic Contrast-Enhanced MRI, and T2-Weighted Imaging
2011
PROSPECTIVE EVALUATION OF PROSTATE CANCER DETECTED ON BIOPSIES 1, 2, 3 AND 4: WHEN SHOULD WE STOP?
2001
Novel Artificial Neural Network for Early Detection of Prostate Cancer
2002
Finasteride for benign prostatic hyperplasia
2010
Prostate Cancer
2001
Diffusion-Weighted MRI in the Body: Applications and Challenges in Oncology
2007 Standout
Design Strategies for Water-Soluble Small Molecular Chromogenic and Fluorogenic Probes
2013 Standout
Cancer de la prostate
2007
Association Between Smoking Status, and Free, Total and Percent Free Prostate Specific Antigen
2012
Works of Eric N.P. Subong being referenced
Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease
1998
Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer
1997
The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer
1996
Preliminary immunohistochemical characterization of a monoclonal antibody (pro:4-216) prepared from human prostate cancer nuclear matrix proteins
1997
Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total psa, prostate volume, and age
1996
Prostate Tissue Composition and Response to Finasteride in Men With Symptomatic Benign Prostatic Hyperplasia
1997
INFLUENCE OF FINASTERIDE ON FREE AND TOTAL SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA
1998
Standard Versus Age-Specific Prostate Specific Antigen Reference Ranges Among Men With Clinically Localized Prostate Cancer: A Pathological Analysis
1996